Obesity is not associated with the poor pregnancy outcome following intracytoplasmic sperm injection in women with polycystic ovary syndrome

Data stored in a computer database on women with PCOS that underwent IVF treatment between May 2007 and August 2012 were retrospectively analyzed. The study protocol was approved by the Etlik Zbeyde Hanim Training and Research Institutional Review Board and written informed consent was obtained from the patients related to the treatment procedure. The study cohort consisted of PCOS patients that met the following criteria: BMI of 18.5-35 kg m -2 ; undergoing ovarian stimulation using the mid-luteal long GnRH agonist protocol or the flexible GnRH antagonist protocol; and age 35 years. Women that underwent freeze-thaw cycles were excluded. All participants were stratified into 3 BMI groups according to the World Health Organization (WHO) classification system for obesity ( kg m -2 [group 1]); overweight (BMI: 25-29.9 kg m -2 [group 2]); and obese (BMI: 30-34.9 kg m -2 [group3]). Patients treated with the mid-luteal long GnRH agonist protocol took an oral contraceptive pill (Desolett; Schering Plough Medical, stanbul, Turkey) for 21 d starting on d 3 of spontaneous menses. The gonadotropin starting dose ranged from 75 IU to 300 IU based on BMI. On d 16, daily GnRH agonist Objective: To determine if body mass index has an effect on the outcome of in vitro fertilization in patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.